SEK 2.07
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only